ARTICANZ - Beta (ver 0.91)
Annotated Registry of Trials in Cancer, Australia and New Zealand Ed.
- Results - target/topoisomerase-inhibitor
Home
By cancer type
By drug class
By site
Data
FAQ
About
⚠
ARTICANZ provides informational content about cancer drug trials in Australia/NZ that is updated weekly but may not be completely accurate, and should not replace medical advice from qualified healthcare professionals. The platform is intended to be useful, providing information "as is" without warranties. Non-medical users must always consult healthcare providers for all clinical decisions.
Search results
target/topoisomerase-inhibitor
45
trial(s) found.
NCT07843940
Advanced
Phase 1 / Phase 2
Recruiting
A Phase Ib/II, Open-label, Safety and Tolerability Trial of Intravenous Obrixtamig in Combination With Pumitamig and Standard of Care (Carboplatin, Etoposide) in Patients With Extensive-stage Small Cell Lung Carcinoma (
1438-0035
)
bispecific PD-L1/VEGFA antibody
bispecific T-cell engager,DLL3-targeting
platinum-based antineoplastic agent
topoisomerase inhibitor
Small-cell lung cancer
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
QLD
4814 - Douglas - Townsville Cancer Centre - The Townsville Hospital
NCT07678593
Advanced
Phase 1 / Phase 2
Recruiting
A Multi-center, Open-label Phase Ib/II Study Exploring the Safety/Tolerability, Pharmacokinetics, and Efficacy of GFH276 in Combination With Cetuximab or Chemotherapy in the Treatment of Patients With Advanced Solid Tumors and Pancreatic Ductal Adenocarcinoma (PDAC) Harboring RAS Mutation (
GFH276X0201
)
anti-EGFR monoclonal antibody
pan-RAS inhibitor,tricomplex inhibitor
+ topoisomerase inhibitor
Cancer
Pancreatic adenocarcinoma
Solid tumour
NSW
2109 - North Ryde - Macquarie University Hospital
2139 - Concord - Concord Repatriation General Hospital
VIC
3066 - Epping - Northern Hospital
3168 - Clayton - Monash Medical Centre
3199 - Frankston - PASO Medical
SA
5011 - Woodville South - The Queen Elizabeth Hospital
NCT07625644
Advanced
Phase 3
Recruiting
A Phase 3 Open-Label, Randomized Controlled Trial of BL-M14D1 and Atezolizumab vs. Standard-of-Care Therapy in Patients With First-Line Extensive-Stage Small Cell Lung Cancer (
BL-M14D1-LC-301
)
anti-DLL3 antibody-drug conjugate,topoisomerase inhibitor 1-payload
anti-PD-L1 monoclonal antibody
Lung cancer
Small-cell lung cancer
Small-cell neuroendocrine carcinoma
ACT
2605 - Garran - The Canberra Hospital
QLD
4215 - Southport - Tasman Oncology
SA
5042 - Bedford Park - Flinders Medical Centre
NCT07544654
Advanced
Phase 3
Recruiting
A Phase III, Multi-center, Open-label, Randomised, Controlled Trial of Intravenous Obrixtamig in Combination With Carboplatin and Etoposide vs. Carboplatin and Etoposide as First-line Therapy in DLL3-positive Patients With Unresectable Locally Advanced or Metastatic Extrapulmonary Neuroendocrine Carcinomas (
1438-0011
)
bispecific T-cell engager,DLL3-targeting
platinum-based antineoplastic agent
topoisomerase inhibitor
Lung neuroendocrine tumour
NSW
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
SA
5042 - Bedford Park - Flinders Medical Centre
WA
6150 - Murdoch - Fiona Stanley Hospital
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NCT07490301
Advanced
Phase 2 / Phase 3
Recruiting
Phase 2/3 Open Label Randomized Study of Telisotuzumab Adizutecan in Combination With FOLFOX Compared to Standard of Care in Subjects With First-Line Metastatic Pancreatic Ductal Adenocarcinoma - AndroMETa-PDAC-288 (
M25-288
)
anti-cMET antibody-drug conjugate
+ topoisomerase inhibitor
Pancreatic adenocarcinoma
VIC
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
NCT07472517
Advanced
Phase 3
Recruiting
DAREON ® -Lung-1: A Phase III Multi-center, Open-label, Randomised Trial of Intravenous Obrixtamig in Combination With Atezolizumab, Carboplatin, and Etoposide vs. Atezolizumab, Carboplatin, and Etoposide as First-line Treatment in Patients With Extensive-stage Small Cell Lung Cancer (
1438-0012
)
anti-PD-L1 monoclonal antibody
bispecific T-cell engager,DLL3-targeting
platinum-based antineoplastic agent
topoisomerase inhibitor
Small-cell lung cancer
NSW
2031 - Randwick - Prince of Wales Hospital
VIC
3350 - Ballarat - Grampians Health Service's Ballarat Base Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NZ.3210 - Hamilton - Waikato Hospital
NCT07415031
Advanced
Phase 2
Recruiting
Solid Tumor Study for Long Term Treatment of Cancer Patients Who Have Participated in BMS Parent Studies Investigating Adagrasib (BMS-986503) (
CA239-0071
)
KRAS G12C inhibitor,OFF-state inhibitor
+ topoisomerase inhibitor
Solid tumour
NSW
2065 - St Leonards - GenesisCare North Shore Private Hospital (WITHDRAWN)
NCT07334301
Paed
Phase 1 / Phase 2
Recruiting
A Multi-Arm, Multi-Stage Platform Trial For Relapsed Neuroblastoma (
BEACON2
)
Bevacizumab
Dinutuximab
Irinotecan
Temozolomide
Topotecan
alkylating agent
anti-GD2 monoclonal antibody
anti-VEGF monoclonal antibody
cancer therapy
cancer therapy,GD2-targeting
cancer therapy,VEGF-targeting
cytotoxic chemotherapy
immuno-oncology therapy,GD2-targeting
immuno-oncology therapy,VEGF-targeting
topoisomerase inhibitor
+ topoisomerase inhibitor
Neuroblastoma
NSW
2031 - Randwick - Sydney Children's Hospital
NZ
NZ.1023 - Grafton - Starship Children's Hospital
NCT07286266
Advanced
Phase 3
Recruiting
A Randomized, Open-label, Multicenter, Phase 3 Study to Investigate Mocertatug Rezetecan Compared With Standard of Care in Participants With Platinum-resistant Ovarian Cancer
anti-B7H4 antibody-drug conjugate
+ topoisomerase inhibitor
Ovarian cancer
NSW
2031 - Randwick - Prince of Wales Hospital
QLD
4066 - Auchenflower - Icon Cancer Centre at Wesley Hospital
NCT07218809
Advanced
Phase 3
Recruiting
A Randomised, Open-label, Phase III Study of AZD5335 Versus Mirvetuximab Soravtansine in FRα-high and AZD5335 Versus Investigator's Choice Chemotherapy in FRα-low Expressing High-grade Platinum-resistant Epithelial Ovarian Cancer Patients (
TREVI-OC-01
)
anti-FR-alpha antibody-drug conjugate
+ topoisomerase inhibitor
Epithelial Ovarian Cancer
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2217 - Kogarah - St George Hospital
2250 - Gosford - Central Coast Cancer Centre, Gosford Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
2487 - Cudgen - Tweed Valley Hospital
2560 - Campbelltown - Macarthur Cancer Therapy Centre - Campbelltown Hospital
ACT
2605 - Garran - The Canberra Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3121 - Richmond - Epworth Freemasons Hospital
3168 - Clayton - Monash Medical Centre
QLD
4066 - Auchenflower - Icon Cancer Centre at Wesley Hospital
SA
5037 - Kurralta Park - Icon Cancer Centre Adelaide
NCT07213804
Advanced
Phase 3
Recruiting
FRAmework-01
: A Three-Part Phase 3 Study of Sofetabart Mipitecan (LY4170156) Versus Chemotherapy or Mirvetuximab Soravtansine in Platinum-Resistant Ovarian Cancer, and Sofetabart Mipitecan Plus Bevacizumab Versus Platinum-Based Chemotherapy Plus Bevacizumab in Platinum-Sensitive Ovarian Cancer.
anti-FR-alpha antibody-drug conjugate
anti-FR-alpha antibody-drug conjugate,topoisomerase inhibitor 1-payload
anti-VEGF monoclonal antibody
Carcinoma
Ovarian cancer
Primary fallopian tube serous carcinoma
NSW
2031 - Randwick - Prince of Wales Hospital
2050 - Camperdown - Chris O'Brien Lifehouse
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
VIC
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre
3350 - Ballarat - Grampians Health Service's Ballarat Base Hospital
3630 - Shepparton - Goulburn Valley Health
3844 - Traralgon - Latrobe Regional Hospital
QLD
4215 - Southport - Gold Coast University Hospital
4814 - Douglas - Townsville Cancer Centre - The Townsville Hospital
TAS
7250 - Launceston - Launceston General Hospital - Northern Cancer Centre
NCT07099898
Advanced
Phase 3
Recruiting
Phase 3, Multicenter, Randomized, Open-label Clinical Study of GSK5764227, a B7-H3 Antibody Drug Conjugate (ADC), Compared With Topotecan in Participants With Relapsed Small Cell Lung Cancer (SCLC)
anti-B7H3 antibody-drug conjugate,topoisomerase inhibitor 1-payload
topoisomerase inhibitor
Small-cell lung cancer
NSW
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
WA
6009 - Nedlands - Linear Clinical Research (WITHDRAWN)
NCT06974110
Advanced
Phase 1
Recruiting
A Phase 1 Study of MOMA-341 as Monotherapy or Combination Therapy in Participants With Advanced or Metastatic Solid Tumors (
MOMA-341-001
)
WRN inhibitor
+ topoisomerase inhibitor
Cancer
Colorectal cancer
Endometrial cancer
Gastric cancer
Solid tumour
NSW
2031 - Randwick - Scientia Clinical Research Ltd
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
VIC
3168 - Clayton - Monash Medical Centre
QLD
4102 - Woolloongabba - Princess Alexandra Hospital (COMPLETED)
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
WA
6009 - Nedlands - Linear Clinical Research
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NCT06801834
Advanced
Phase 3
Recruiting
A Global, Multicenter, Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan Versus Standard of Care (SOC) in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer (ES-SCLC) (
EVOKE-SCLC-04
)
anti-Trop2 antibody-drug conjugate
+ topoisomerase inhibitor
Small-cell lung cancer
NSW
2500 - Wollongong - Cancer Care Wollongong
VIC
3065 - Fitzroy - St Vincent's Hospital Melbourne
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
4215 - Southport - Gold Coast University Hospital
SA
5000 - Adelaide - Cancer Research SA
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NCT06792695
Advanced
Phase 2
Recruiting
A Phase II, Open-label, Multicenter, Master Protocol to Evaluate the Safety and Efficacy of Novel Study Interventions and Combinations in Participants With Colorectal Cancer (
CANTOR
)
Bevacizumab
Fluorouracil
Irinotecan
Leucovorin
Volrustomig
anti-VEGF monoclonal antibody
antimetabolite
bispecific PD-L1/CTLA4 antibody
cancer therapy
cancer therapy,CTLA4-targeting
cancer therapy,PD-1/PD-L1-targeting
cancer therapy,PD-L1-targeting
cancer therapy,VEGF-targeting
cytotoxic chemotherapy
fluoropyrimidine
immune checkpoint blockade
immune checkpoint blockade,CTLA4-targeting
immune checkpoint blockade,PD-L1-targeting
immuno-oncology therapy,CTLA4-targeting
immuno-oncology therapy,PD-L1-targeting
immuno-oncology therapy,VEGF-targeting
therapeutic modality,bispecific antibody
topoisomerase inhibitor
+ topoisomerase inhibitor
Colorectal adenocarcinoma
NSW
2500 - Wollongong - Wollongong Hospital
VIC
3002 - East Melbourne - Epworth Freemasons
SA
5011 - Woodville South - The Queen Elizabeth Hospital
NCT06750094
Advanced
Phase 3
Recruiting
A Randomized, Open-label Phase 3 Study of Amivantamab + FOLFIRI Versus Cetuximab/Bevacizumab + FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Recurrent, Unresectable or Metastatic Colorectal Cancer Who Have Received Prior Chemotherapy (
OrigAMI-3
)
anti-EGFR monoclonal antibody
anti-VEGF monoclonal antibody
bispecific cMET/EGFR antibody
+ topoisomerase inhibitor
Colorectal adenocarcinoma
NSW
2139 - Concord - Concord Repatriation General Hospital (COMPLETED)
VIC
3021 - St Albans - Western Health - Sunshine Hospital
3084 - Heidelberg - Warringal Private Hospital
SA
5011 - Woodville South - The Queen Elizabeth Hospital
NCT06741644
Advanced
Phase 1 / Phase 2
Recruiting
A Phase I/II, Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activities of CS2009, a Tri-specific Antibody Targeting PD-1/VEGFA/CTLA-4, as Monotherapy and Combination Therapy in Participants With Advanced Solid Tumors (
CS2009-101
)
trispecific PD-1/VEGFA/CTLA4 antibody
+ topoisomerase inhibitor
Solid tumour
NSW
2031 - Randwick - Scientia Clinical Research Ltd
2109 - North Ryde - Macquarie University Hospital
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3004 - Melbourne, Southbank - Alfred Health
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3168 - Clayton - Monash Medical Centre
QLD
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
NCT06712355
Advanced
Phase 3
Recruiting
A Phase III, Multisite, Double-blinded Randomized Trial of BNT327 in Combination With Chemotherapy (Etoposide/Carboplatin) Compared to Atezolizumab in Combination With Chemotherapy (Etoposide/Carboplatin) in Participants With First-line Extensive-stage Small-cell Lung Cancer (
BNT327-03
)
anti-PD-L1 monoclonal antibody
bispecific PD-L1/VEGFA antibody
platinum-based antineoplastic agent
topoisomerase inhibitor
Small-cell lung cancer
NSW
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2170 - Liverpool - Liverpool Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
2500 - Wollongong - Cancer Care Wollongong
VIC
3021 - St Albans - Western Health - Sunshine Hospital
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3199 - Frankston - Peninsula Health Frankston Hospital
QLD
4870 - Cairns - Cairns Base Hospital
SA
5011 - Woodville South - The Queen Elizabeth Hospital
5037 - Kurralta Park - Icon Cancer Centre Adelaide
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NCT06646276
Advanced
Phase 3
Recruiting
A Randomized, Double Blind, Multicenter Phase 3 Trial of BMS-986489 (Atigotatug+Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide vs Atezolizumab in Combination With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS). (
CA245-0001
)
anti-PD-1 monoclonal antibody
anti-PD-L1 monoclonal antibody
anti-fucosyl-GM1 monoclonal antibody
platinum-based antineoplastic agent
topoisomerase inhibitor
Small-cell lung cancer
NSW
2560 - Campbelltown - Macarthur Cancer Therapy Centre - Campbelltown Hospital
2747 - Kingswood - Nepean Hospital - Nepean Cancer Care Centre
VIC
3350 - Ballarat - Grampians Health Service's Ballarat Base Hospital (COMPLETED)
QLD
4120 - Greenslopes - Greenslopes Private Hospital
WA
6150 - Murdoch - Fiona Stanley Hospital
NCT06401330
Paed
Phase 3
Recruiting
Risk Adapted Treatment of Unilateral Favorable Histology Wilms Tumors (FHWT) (
AREN2231
)
Carboplatin
Cyclophosphamide
Dactinomycin
Doxorubicin
Etoposide
Irinotecan
Vincristine
alkylating agent
anthracycline
antineoplastic antibiotic
cancer therapy
cytotoxic chemotherapy
platinum-based antineoplastic agent
topoisomerase inhibitor
vinca alkaloid
+ topoisomerase inhibitor
Wilms tumour
QLD
4101 - South Brisbane - Queensland Children's Hospital
NZ
NZ.1023 - Grafton - Starship Children's Hospital
NZ.8011 - Christchurch - Canterbury District Health Board - Christchurch Hospital Cancer Centre
NCT06219941
Advanced
Phase 2
Recruiting
A Phase II, Open-label, Multi-centre Study to Evaluate Safety, Tolerability, Efficacy, PK, and Immunogenicity of AZD0901 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Tumours Expressing Claudin 18.2 (CLARITY-PanTumour01) (
D9800C00001
)
anti-CLDN18.2 antibody-drug conjugate
+ topoisomerase inhibitor
Biliary tract cancer
Gastric cancer
Gastroesophageal junction adenocarcinoma
NSW
2031 - Randwick - Prince of Wales Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
WA
6150 - Murdoch - Fiona Stanley Hospital
NCT06208657
Paed
Phase 1 / Phase 2
Recruiting
Optimal Precision TherapIes to CustoMISE Care in Childhood and Adolescent Cancer (
OPTIMISE
)
Irinotecan
Nivolumab
PI3K alpha inhibitor
PI3K delta inhibitor
PI3K inhibitor
Paxalisib
Relatlimab
Temozolomide
alkylating agent
anti-LAG3 monoclonal antibody
anti-PD-1 monoclonal antibody
cancer therapy
cancer therapy,LAG3-targeting
cancer therapy,PD-1-targeting
cancer therapy,PD-1/PD-L1-targeting
cancer therapy,PI3K-targeting
cancer therapy,PI3K delta-targeting
cancer therapy,PI3Kalpha-targeting
cancer therapy,mTOR-targeting
cancer therapy,mTORC1-targeting
cancer therapy,mTORC2-targeting
cytotoxic chemotherapy
dual PI3K/mTOR inhibitor
immune checkpoint blockade
immune checkpoint blockade,LAG3-targeting
immune checkpoint blockade,PD-1-targeting
immuno-oncology therapy,LAG3-targeting
immuno-oncology therapy,PD-1-targeting
mTORC1/mTORC2 inhibitor
mTORC1 inhibitor
mTORC2 inhibitor
mTOR inhibitor
topoisomerase inhibitor
+ topoisomerase inhibitor
Cancer
Central nervous system cancer
Solid tumour
NSW
2031 - Randwick - Sydney Children's Hospital
2145 - Westmead - The Children's Hospital at Westmead
2305 - New Lambton Heights - John Hunter Children's Hospital
VIC
3052 - Parkville - Royal Children's Hospital Melbourne
3168 - Clayton - Monash Children's Hospital
QLD
4101 - South Brisbane - Queensland Children's Hospital
SA
5006 - North Adelaide - Women's and Children's Hospital-Adelaide Cancer Centre
WA
6009 - Perth - Perth Children's Hospital
TAS
7000 - Hobart - Royal Hobart Hospital
NCT06203210
Advanced
Phase 3
Recruiting
A Phase 3, Multicenter, Randomized, Open-label Study of Ifinatamab Deruxtecan (I-DXd), a B7-H3 Antibody Drug Conjugate (ADC), Versus Treatment of Physician's Choice (TPC) in Subjects With Relapsed Small Cell Lung Cancer (SCLC) (
IDeate-Lung02
)
anti-B7H3 antibody-drug conjugate,topoisomerase inhibitor 1-payload
Small-cell lung cancer
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
VIC
3021 - St Albans - Western Health - Sunshine Hospital
3350 - Ballarat - Grampians Health Service's Ballarat Base Hospital
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
4814 - Douglas - Townsville Cancer Centre - The Townsville Hospital
SA
5042 - Bedford Park - Flinders Medical Centre
WA
6008 - Subiaco - Bendat Family Comprehensive Cancer Centre - St John of God Subiaco Hospital
NCT06161025
Advanced
Phase 2 / Phase 3
Recruiting
A Phase 2/3, Multicenter, Randomized Study of Raludotatug Deruxtecan (R-DXd), a CDH6-directed Antibody-drug Conjugate, in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer (
DS6000-109
)
anti-CDH6 antibody-drug conjugate
+ topoisomerase inhibitor
High-grade serous ovarian cancer
NOT Ovarian cancer
NOT Ovarian mucinous carcinoma
Ovarian endometrioid adenocarcinoma
Peritoneal cancer
Primary fallopian tube serous carcinoma
NSW
2065 - St Leonards - GenesisCare North Shore Private Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
QLD
4215 - Southport - Gold Coast University Hospital
SA
5000 - South Australia - GenesisCare St Andrews Hospital
NCT05999994
Paed
Phase 2
Recruiting
CAMPFIRE
: Children's and Young Adult Master Protocol for Innovative Pediatric Research
Abemaciclib
CDK4/6 inhibitor
CDK4 inhibitor
CDK6 inhibitor
Cyclophosphamide
Docetaxel
Gemcitabine
Irinotecan
Ramucirumab
Temozolomide
Vinorelbine
alkylating agent
anti-VEGFR2 monoclonal antibody
antimetabolite
cancer therapy
cancer therapy,CDK4-targeting
cancer therapy,CDK6-targeting
cancer therapy,VEGFR2-targeting
cytotoxic chemotherapy
immuno-oncology therapy,VEGFR2-targeting
taxane
topoisomerase inhibitor
vinca alkaloid
+ topoisomerase inhibitor
Cancer
NSW
2050 - Camperdown - Chris O'Brien Lifehouse (COMPLETED)
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre (COMPLETED)
3053 - Parkville - The Royal Women's Hospital and Institute of Maternal and Child Health (COMPLETED)
NCT05991388
Paed
Phase 2 / Phase 3
Recruiting
A Global Study of Novel Agents in Paediatric and Adolescent Relapsed and Refractory B-cell Non-Hodgkin Lymphoma (
Glo-BNHL
)
Carboplatin
Dexamethasone
Etoposide
Ifosfamide
Loncastuximab Tesirine
Odronextamab
Rituximab
alkylating agent
anti-CD19 antibody-drug conjugate
anti-CD20 monoclonal antibody
bispecific T-cell engager,CD20-targeting
cancer therapy
cancer therapy,CD19-targeting
cancer therapy,CD20-targeting
cytotoxic chemotherapy
glucocorticoid
immuno-oncology therapy,CD19-targeting
immuno-oncology therapy,CD20-targeting
platinum-based antineoplastic agent
therapeutic modality,bispecific T-cell engager
therapeutic modality,bispecific antibody
topoisomerase inhibitor
+ topoisomerase inhibitor
Non-Hodgkin's lymphoma
NSW
2145 - Westmead - The Children's Hospital at Westmead
QLD
4101 - South Brisbane - Queensland Children's Hospital
WA
6009 - Perth - Perth Children's Hospital
NZ
NZ.1023 - Grafton - Starship Children's Hospital
NCT05533775
Paed
Phase 1 / Phase 2
Recruiting
A Phase I/II, Open-Label, Single-Arm, Two-Part Trial to Evaluate Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of Glofitamab in Monotherapy and in Combination With Chemoimmunotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Mature B-Cell Non-Hodgkin Lymphoma (
iMATRIX-GLO
)
bispecific T-cell engager,CD20-targeting
+ topoisomerase inhibitor
Non-Hodgkin's lymphoma
QLD
4101 - South Brisbane - Queensland Children's Hospital
WA
6009 - Perth - Perth Children's Hospital
NCT05504291
Paed
Phase 2
Recruiting
Intravitreal Melphalan for Intraocular Retinoblastoma (
ARET2121
)
alkylating agent
+ topoisomerase inhibitor
Retinoblastoma
VIC
3052 - Parkville - Royal Children's Hospital Melbourne (SUSPENDED)
WA
6009 - Perth - Perth Children's Hospital (SUSPENDED)
NCT05203172
Advanced
Phase 4
Recruiting
ENCORAFENIB/BINIMETINIB MASTER PROTOCOL: AN OPEN-LABEL CONTINUATION STUDY FOR PARTICIPANTS CONTINUING FROM ENCORAFENIB/BINIMETINIB CLINICAL STUDIES (
C4221026
)
BRAF V600 inhibitor
MEK inhibitor
+ topoisomerase inhibitor
Solid tumour
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
NCT04684368
Radonc
Phase 2
Recruiting
A Phase 2 Trial of Chemotherapy Followed by Response-Based Whole Ventricular &Amp; Spinal Canal Irradiation (WVSCI) for Patients With Localized Non-Germinomatous Central Nervous System Germ Cell Tumor (
ACNS2021
)
Carboplatin
Etoposide
Filgrastim
Ifosfamide
Mesna
Pegfilgrastim
Radiotherapy
Thiotepa
alkylating agent
cancer therapy
cytotoxic chemotherapy
platinum-based antineoplastic agent
sodium mercaptoethanesulfonate
topoisomerase inhibitor
+ topoisomerase inhibitor
Choriocarcinoma
Germ cell tumour
Germinoma
Mixed germ cell tumour
Teratoma
Testicular embryonal carcinoma
Yolk sac tumour
NSW
2031 - Randwick - Sydney Children's Hospital
2145 - Westmead - The Children's Hospital at Westmead
VIC
3052 - Parkville - Royal Children's Hospital Melbourne
QLD
4101 - South Brisbane - Queensland Children's Hospital
SA
5006 - North Adelaide - Calvary North Adelaide Hospital, Adelaide Oncology & Haematology
WA
6009 - Perth - Perth Children's Hospital
NZ
NZ.8011 - Christchurch - Canterbury District Health Board - Christchurch Hospital Cancer Centre
NCT04625907
Radonc
Phase 1 / Phase 2
Recruiting
FaR-RMS
: An Overarching Study for Children and Adults With Frontline and Relapsed RhabdoMyoSarcoma
Cyclophosphamide
Dactinomycin
Doxorubicin
FGFR1/2/3 inhibitor
FGFR1 inhibitor
FGFR2 inhibitor
FGFR3 inhibitor
FGFR4 inhibitor
FGFR inhibitor
Ifosfamide
Irinotecan
KIT/PDGFR/RET/VEGFR/FGFR inhibitor
KIT inhibitor
KIT inhibitor,first generation
PDGFR inhibitor
RET inhibitor
Radiotherapy
Regorafenib
Temozolomide
VEGFR inhibitor
Vincristine
Vinorelbine
alkylating agent
anthracycline
antineoplastic antibiotic
cancer therapy
cancer therapy,FGFR-targeting
cancer therapy,FGFR1-targeting
cancer therapy,FGFR1/2/3-targeting
cancer therapy,FGFR2-targeting
cancer therapy,FGFR3-targeting
cancer therapy,FGFR4-targeting
cancer therapy,KIT-targeting
cancer therapy,PDGFR-targeting
cancer therapy,RET-targeting
cancer therapy,VEGFR-targeting
cytotoxic chemotherapy
pan-FGFR inhibitor
pan-FGFR inhibitor,reversible
topoisomerase inhibitor
vinca alkaloid
+ topoisomerase inhibitor
Rhabdomyosarcoma
NSW
2031 - Randwick - Sydney Children's Hospital
2050 - Camperdown - Chris O'Brien Lifehouse
2145 - Westmead - The Children's Hospital at Westmead
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
2305 - New Lambton Heights - John Hunter Children's Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3052 - Parkville - Royal Children's Hospital Melbourne
3168 - Clayton - Monash Children's Hospital
QLD
4101 - South Brisbane - Queensland Children's Hospital
4102 - Woolloongabba - Princess Alexandra Hospital
WA
6009 - Perth - Perth Children's Hospital
NZ
NZ.1023 - Grafton - Starship Children's Hospital
NZ.8011 - Christchurch - Canterbury District Health Board - Christchurch Hospital Cancer Centre
NCT04322318
Advanced
Phase 2
Recruiting
Treatment of Newly Diagnosed Diffuse Anaplastic Wilms Tumors (DAWT) and Relapsed Favorable Histology Wilms Tumors (FHWT) (
AREN1921
)
Carboplatin
Cyclophosphamide
Doxorubicin
Etoposide
Ifosfamide
Irinotecan
Radiotherapy
Topotecan
Vincristine
alkylating agent
anthracycline
cancer therapy
cytotoxic chemotherapy
platinum-based antineoplastic agent
topoisomerase inhibitor
vinca alkaloid
+ topoisomerase inhibitor
Wilms tumour
NSW
2031 - Randwick - Sydney Children's Hospital (SUSPENDED)
2145 - Westmead - The Children's Hospital at Westmead (SUSPENDED)
2305 - New Lambton Heights - John Hunter Children's Hospital (SUSPENDED)
VIC
3052 - Parkville - Royal Children's Hospital Melbourne
3168 - Clayton - Monash Medical Centre (SUSPENDED)
QLD
4101 - South Brisbane - Queensland Children's Hospital
SA
5006 - North Adelaide - Calvary North Adelaide Hospital, Adelaide Oncology & Haematology (SUSPENDED)
WA
6009 - Perth - Perth Children's Hospital
NZ
NZ.1023 - Grafton - Starship Children's Hospital
NZ.8011 - Christchurch - Canterbury District Health Board - Christchurch Hospital Cancer Centre
NCT04293562
Paed
Phase 3
Recruiting
A Phase 3 Randomized Trial for Patients With De Novo AML Comparing Standard Therapy Including Gemtuzumab Ozogamicin (GO) to CPX-351 With GO, and the Addition of the FLT3 Inhibitor Gilteritinib for Patients With FLT3 Mutations (
AAML1831
)
AXL/FLT3 inhibitor
anti-CD33 antibody-drug conjugate
liposomal cytarabine/daunorubicin
+ topoisomerase inhibitor
Acute myeloid leukaemia
NSW
2031 - Randwick - Sydney Children's Hospital
2145 - Westmead - The Children's Hospital at Westmead
QLD
4101 - South Brisbane - Queensland Children's Hospital (SUSPENDED)
WA
6009 - Perth - Perth Children's Hospital
NCT04221035
Radonc
Phase 3
Recruiting
High-Risk Neuroblastoma Study 2 of SIOP-Europa-Neuroblastoma (SIOPEN) (
HR-NBL2
)
Busulfan
Carboplatin
Cisplatin
Cyclophosphamide
Dacarbazine
Dinutuximab
Doxorubicin
Etoposide
Ifosfamide
Irinotecan
Melphalan
Radiotherapy
Temozolomide
Thiotepa
Vincristine
alkylating agent
anthracycline
anti-GD2 monoclonal antibody
cancer therapy
cancer therapy,GD2-targeting
cytotoxic chemotherapy
immuno-oncology therapy,GD2-targeting
platinum-based antineoplastic agent
topoisomerase inhibitor
vinca alkaloid
+ topoisomerase inhibitor
Neuroblastoma
NSW
2031 - Randwick - Sydney Children's Hospital
2305 - New Lambton Heights - John Hunter Children's Hospital
2145 - Westmead - The Children's Hospital at Westmead (SUSPENDED)
VIC
3186 - Brighton - Cabrini Hospital Brighton Cancer Centre
WA
6009 - Perth - Perth Children's Hospital (SUSPENDED)
NCT02582697
Advanced
Phase 3
Recruiting
Phase 3 Accelerated BEP: A Randomised Phase 3 Trial of Accelerated Versus Standard BEP Chemotherapy for Patients With Intermediate and Poor-risk Metastatic Germ Cell Tumours (
P3BEP
)
Bleomycin
Cisplatin
Etoposide
Filgrastim
Pegfilgrastim
antineoplastic antibiotic
cancer therapy
cytotoxic chemotherapy
platinum-based antineoplastic agent
topoisomerase inhibitor
+ topoisomerase inhibitor
Germ cell tumour
NSW
2031 - Randwick - Prince of Wales Hospital
2050 - Camperdown - Chris O'Brien Lifehouse
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2076 - Wahroonga - Sydney Adventist Hospital
2109 - North Ryde - Macquarie University Hospital
2139 - Concord - Concord Repatriation General Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
2747 - Kingswood - Nepean Hospital - Nepean Cancer Care Centre
VIC
3002 - Melbourne - Peter MacCallum Cancer Centre, East Melbourne campus
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3128 - Box Hill - Box Hill Hospital - Eastern Health
3690 - Wodonga - Border Medical Oncology at Wodonga Regional Cancer Centre
3021 - St Albans - Western Health - Sunshine Hospital (WITHDRAWN)
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
4101 - South Brisbane - Queensland Children's Hospital
4102 - Woolloongabba - Princess Alexandra Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
5042 - Bedford Park - Flinders Medical Centre
WA
6150 - Murdoch - Fiona Stanley Hospital
TAS
7000 - Hobart - Royal Hobart Hospital
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NZ.1023 - Grafton - Starship Children's Hospital
NZ.4442 - Roslyn - Palmerston North Hospital Cancer Centre - Palmerston North Hospital
NZ.8011 - Christchurch - Canterbury District Health Board - Christchurch Hospital Cancer Centre
NZ.9016 - Dunedin - Dunedin Hospital (WITHDRAWN)
ACTRN12624001230549
Curative
Phase 2 / Phase 3
Not yet recruiting
An assessment of cancer outcomes post cytoreductive surgery and intraperitoneal chemotherapy for colorectal peritoneal metastases with the use of a personalised aproach to choice of intraperitoneal chemotherapy agent individualised to a patient's specific tumour sensitivity in-vitro.
Irinotecan
Mitomycin
Oxaliplatin
antineoplastic antibiotic
cancer therapy
cytotoxic chemotherapy
platinum-based antineoplastic agent
topoisomerase inhibitor
+ topoisomerase inhibitor
Colorectal cancer
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2217 - Kogarah - St George Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
QLD
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
4102 - Woolloongabba - Princess Alexandra Hospital
SA
5011 - Woodville South - The Queen Elizabeth Hospital
WA
6027 - Joondalup - Joondalup Health Campus
ACTRN12624000005550
Curative
Phase 3
Recruiting
Efficacy of Neoadjuvant FOLFIRINOX in Resectable pancreatic cancer: An international multicenter prospective randomized, controlled trial (
NeoFOL-R
)
Filgrastim
Fluorouracil
Irinotecan
Leucovorin
Oxaliplatin
antimetabolite
cancer therapy
cytotoxic chemotherapy
fluoropyrimidine
platinum-based antineoplastic agent
topoisomerase inhibitor
+ topoisomerase inhibitor
Pancreatic cancer
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
VIC
3002 - East Melbourne - Epworth Freemasons
3004 - Melbourne, Southbank - Alfred Health
3011 - Footscray - Footscray Hospital
3066 - Epping - Northern Hospital
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3121 - Richmond - Epworth Freemasons Hospital
3168 - Clayton - Monash Medical Centre
ACTRN12623000874617
Advanced
Phase 2
Recruiting
Phase II single arm study to explore the efficacy of cetuximab (in combination with irinotecan based treatment) in advanced stage RAS/BRAF wild-type right-sided colorectal cancer with high AREG/EREG expression (
Biomarcer-2
)
anti-EGFR monoclonal antibody
topoisomerase inhibitor
Colorectal cancer
NSW
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
2305 - New Lambton Heights - Hunter New England Cancer Centre - John Hunter Hospital
2340 - Tamworth - Tamworth Hospital-North West Cancer Centre
ACT
2605 - Garran - The Canberra Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3011 - Footscray - Footscray Hospital
3066 - Epping - Northern Hospital
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre
3280 - Warrnambool - South West Healthcare, Warrnambool Base Hospital, Oncology Unit
3844 - Traralgon - Latrobe Regional Hospital
WA
6150 - Murdoch - Fiona Stanley Hospital
ACTRN12621000586819
Radonc
Phase 2
Recruiting
A phase II study of platinum and etoposide chemotherapy, durvalumab with thoracic radiotherapy in the first line treatment of patients with extensive-stage small-cell lung cancer (
TROG-20.01-CHEST-RT
)
anti-PD-L1 monoclonal antibody
radiotherapy
topoisomerase inhibitor
Cancer
Lung cancer
Small-cell lung cancer
NSW
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre
2170 - Liverpool - Liverpool Hospital
VIC
3066 - Epping - Northern Hospital
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
4102 - Woolloongabba - Princess Alexandra Hospital
ACTRN12617001571369
Radonc
Not yet recruiting
Effect of Stereotactic ablative body radiotherapy for Unresectable Pancreatic cancer with Endoscopic ultrasound inserted fiducial markers and concuRrent chemotherapy on survival rates: SUPER trial.
radiotherapy
+ topoisomerase inhibitor
Cancer
Pancreatic cancer
ACTRN12611000728932
Advanced
Phase 2
Recruiting
A Randomised trial of predictive assay-directed chemotherapy in non-small cell lung cancer (NSCLC) and mesothelioma
Carboplatin
Docetaxel
Gemcitabine
Irinotecan
Nab-paclitaxel
Paclitaxel
Pemetrexed
antimetabolite
cancer therapy
cytotoxic chemotherapy
platinum-based antineoplastic agent
taxane
topoisomerase inhibitor
+ topoisomerase inhibitor
Lung cancer
Mesothelioma
Non-small cell lung cancer
ACTRN12611000520932
Advanced
Phase 1 / Phase 2
Recruiting
A Phase I/IIa trial of HA-Irinotecan, a formulation of hyaluronic acid and irinotecan, in the treatment of extensive stage small cell lung cancer and its effect on tumour stem cells. (
HA-Irinotecan-small-cell-lung-cancer-trial
)
hyaluronic acid
topoisomerase inhibitor
Small-cell lung cancer
ACTRN12605000119695
Advanced
Phase 2
Recruiting
Randomised Phase II trial of irinotecan with hyaluronic acid (HyCAMP) versus irinotecan as treatment for patients with metastatic colorectal cancer who have failed 5-FU based chemotherapy (CTA 2004) ............incidence of grade 3 or 4 diarrhoea. (
HyCAMP-Phase-II
)
fluoropyrimidine
hyaluronic acid
topoisomerase inhibitor
Colorectal adenocarcinoma
NCT05462236
Advanced
Phase 2
Unknown
A Phase II Open Label, Dose-finding run-in and Cohort Expansion Study to Evaluate the Safety, Tolerability and Effectiveness of Tinodasertib in Combination With Pembrolizumab or Irinotecan in Metastatic Colorectal Cancer (
AUM001-2001-MK3475-D65
)
MNK1/2 inhibitor
anti-PD-1 monoclonal antibody
topoisomerase inhibitor
Colorectal cancer
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2500 - Wollongong - Wollongong Hospital
VIC
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre
3355 - Wendouree - Ballarat Oncology & Haematology Clinical Trials Unit
QLD
4217 - Benowa - Pindara Private Hospital
ACTRN12617001190392
Advanced
Phase 1 / Phase 2
Status unknown
An open label phase IB/II, non-randomised, dose-finding, safety and tolerability study of Panitumumab, Irinotecan, Trifluridine/Tipiracil in RAS wild-type patients with metastatic colorectal cancer (
PIT-Study
)
Tipiracil Hydrochloride
Trifluridine
anti-EGFR monoclonal antibody
antimetabolite
thymidine phosphorylase inhibitor
topoisomerase inhibitor
Colorectal cancer
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
5011 - Woodville South - The Queen Elizabeth Hospital
5042 - Bedford Park - Flinders Medical Centre
Additional search terms:
API and Webpage URLs:
Copy /Bookmark
Filters
Recruitment Status
Recruiting (41)
Not yet recruiting (2)
Unknown (1)
Status unknown (1)
Recruitment Country and State
NSW (30)
VIC (28)
QLD (23)
SA (17)
WA (17)
NZ (9)
ACT (3)
TAS (3)
Phase
Phase 1 (1)
Phase 1 / Phase 2 (9)
Phase 2 (12)
Phase 2 / Phase 3 (4)
Phase 3 (17)
Phase 4 (1)
Trial Type
Advanced (30)
Paed (8)
Radonc (5)
Curative (2)
Paed (1)
Cancer Therapy Class
PD-1/PD-L1
29%
PD-L1
16%
PD-1
16%
EGFR
13%
VEGF
13%
DLL3
7%
VEGFA
7%
KRAS
4%
MET
4%
GD2
4%
FR-alpha
4%
B7H3
4%
CTLA4
4%
CDK4
4%
CDK6
4%
CD20
4%
B7H4
2%
WRN
2%
Trop2
2%
fucosyl-GM1
2%
CLDN18.2
2%
LAG3
2%
PI3K
2%
PI3K delta
2%
PI3Kalpha
2%
mTOR
2%
mTORC1
2%
mTORC2
2%
CDH6
2%
VEGFR2
2%
CD19
2%
IL-6
2%
BRAF
2%
BRAF V600
2%
MEK
2%
RAF
2%
FGFR
2%
FGFR1
2%
FGFR1/2/3
2%
FGFR2
2%
FGFR3
2%
FGFR4
2%
KIT
2%
PDGFR
2%
RET
2%
VEGFR
2%
AXL
2%
CD33
2%
FLT3
2%
MNK
2%
Facility
3000 - Melbourne - Peter MacCallum Cancer Centre (11)
2050 - Camperdown - Chris O'Brien Lifehouse (10)
4101 - South Brisbane - Queensland Children's Hospital (9)
6009 - Perth - Perth Children's Hospital (9)
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre (8)
2031 - Randwick - Sydney Children's Hospital (7)
2145 - Westmead - The Children's Hospital at Westmead (7)
3168 - Clayton - Monash Medical Centre (6)
5011 - Woodville South - The Queen Elizabeth Hospital (6)
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital (6)
NZ.1023 - Grafton - Starship Children's Hospital (6)
4102 - Woolloongabba - Princess Alexandra Hospital (6)
5042 - Bedford Park - Flinders Medical Centre (5)
6150 - Murdoch - Fiona Stanley Hospital (5)
2031 - Randwick - Prince of Wales Hospital (5)
NZ.8011 - Christchurch - Canterbury District Health Board - Christchurch Hospital Cancer Centre (5)
3052 - Parkville - Royal Children's Hospital Melbourne (5)
3066 - Epping - Northern Hospital (4)
3350 - Ballarat - Grampians Health Service's Ballarat Base Hospital (4)
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre (4)
2298 - Waratah - Calvary Mater Newcastle Medical Oncology (4)
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital (4)
3021 - St Albans - Western Health - Sunshine Hospital (4)
2305 - New Lambton Heights - John Hunter Children's Hospital (4)
4814 - Douglas - Townsville Cancer Centre - The Townsville Hospital (3)
2109 - North Ryde - Macquarie University Hospital (3)
2139 - Concord - Concord Repatriation General Hospital (3)
2605 - Garran - The Canberra Hospital (3)
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research (3)
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre (3)
4215 - Southport - Gold Coast University Hospital (3)
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre (3)
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre (3)
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre (3)
2065 - St Leonards - GenesisCare North Shore Private Hospital (2)
4066 - Auchenflower - Icon Cancer Centre at Wesley Hospital (2)
2217 - Kogarah - St George Hospital (2)
2560 - Campbelltown - Macarthur Cancer Therapy Centre - Campbelltown Hospital (2)
3121 - Richmond - Epworth Freemasons Hospital (2)
5037 - Kurralta Park - Icon Cancer Centre Adelaide (2)
3844 - Traralgon - Latrobe Regional Hospital (2)
6009 - Nedlands - Linear Clinical Research (2)
2031 - Randwick - Scientia Clinical Research Ltd (2)
2500 - Wollongong - Cancer Care Wollongong (2)
2500 - Wollongong - Wollongong Hospital (2)
3002 - East Melbourne - Epworth Freemasons (2)
3004 - Melbourne, Southbank - Alfred Health (2)
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre (2)
2170 - Liverpool - Liverpool Hospital (2)
2747 - Kingswood - Nepean Hospital - Nepean Cancer Care Centre (2)
3168 - Clayton - Monash Children's Hospital (2)
7000 - Hobart - Royal Hobart Hospital (2)
5006 - North Adelaide - Calvary North Adelaide Hospital, Adelaide Oncology & Haematology (2)
3011 - Footscray - Footscray Hospital (2)
3199 - Frankston - PASO Medical (1)
4215 - Southport - Tasman Oncology (1)
NZ.3210 - Hamilton - Waikato Hospital (1)
2250 - Gosford - Central Coast Cancer Centre, Gosford Hospital (1)
2487 - Cudgen - Tweed Valley Hospital (1)
3630 - Shepparton - Goulburn Valley Health (1)
7250 - Launceston - Launceston General Hospital - Northern Cancer Centre (1)
3065 - Fitzroy - St Vincent's Hospital Melbourne (1)
5000 - Adelaide - Cancer Research SA (1)
3084 - Heidelberg - Warringal Private Hospital (1)
3199 - Frankston - Peninsula Health Frankston Hospital (1)
4870 - Cairns - Cairns Base Hospital (1)
4120 - Greenslopes - Greenslopes Private Hospital (1)
5006 - North Adelaide - Women's and Children's Hospital-Adelaide Cancer Centre (1)
6008 - Subiaco - Bendat Family Comprehensive Cancer Centre - St John of God Subiaco Hospital (1)
5000 - South Australia - GenesisCare St Andrews Hospital (1)
3053 - Parkville - The Royal Women's Hospital and Institute of Maternal and Child Health (1)
3186 - Brighton - Cabrini Hospital Brighton Cancer Centre (1)
2076 - Wahroonga - Sydney Adventist Hospital (1)
3002 - Melbourne - Peter MacCallum Cancer Centre, East Melbourne campus (1)
3128 - Box Hill - Box Hill Hospital - Eastern Health (1)
3690 - Wodonga - Border Medical Oncology at Wodonga Regional Cancer Centre (1)
NZ.4442 - Roslyn - Palmerston North Hospital Cancer Centre - Palmerston North Hospital (1)
NZ.9016 - Dunedin - Dunedin Hospital (1)
6027 - Joondalup - Joondalup Health Campus (1)
2305 - New Lambton Heights - Hunter New England Cancer Centre - John Hunter Hospital (1)
2340 - Tamworth - Tamworth Hospital-North West Cancer Centre (1)
3280 - Warrnambool - South West Healthcare, Warrnambool Base Hospital, Oncology Unit (1)
3355 - Wendouree - Ballarat Oncology & Haematology Clinical Trials Unit (1)
4217 - Benowa - Pindara Private Hospital (1)
Cancer Type
Cancer
Solid tumour
Thoracic cancer
Gastrointestinal cancer
Lung cancer
Respiratory tract cancer
Carcinoma
Neuroendocrine carcinoma
Small-cell lung cancer
Small-cell neuroendocrine carcinoma
Colorectal cancer
Lower gastrointestinal cancer
Upper gastrointestinal cancer
Pancreatobiliary cancer
Gynaecological cancer
Pancreatic cancer
Neurological cancer
Ovarian cancer
Sarcoma
Epithelial Ovarian Cancer
Colorectal adenocarcinoma
Haematological malignancy
Exocrine pancreatic cancer
Pancreatic adenocarcinoma
Neuroblastic tumour
Neuroblastoma
Peripheral nervous system tumour
Fallopian tube cancer
High-grade serous carcinoma of the ovary, fallopian tube, and peritoneum
Primary fallopian tube serous carcinoma
Gastric cancer
Gastroesophageal cancer
Wilms tumour
Central nervous system cancer
Lymphoma
Non-Hodgkin's lymphoma
Germ cell tumour
Urogenital cancer
Lung neuroendocrine tumour
Neuroendocrine tumour
Endometrial cancer
Biliary tract cancer
Gastric carcinoma
Gastroesophageal junction adenocarcinoma
Hepatobiliary cancer
Oesophageal cancer
High-grade serous ovarian cancer
Ovarian adenocarcinoma
Ovarian endometrioid adenocarcinoma
Ovarian serous carcinoma
Peritoneal cancer
Retinoblastoma
Choriocarcinoma
Germinoma
Male genital cancers
Mixed germ cell tumour
Non-seminoma
Teratoma
Testicular cancer
Testicular embryonal carcinoma
Yolk sac tumour
Rhabdomyosarcoma
Soft tissue sarcoma
Acute myeloid leukaemia
Leukaemia
Myeloid leukaemia
Mesothelioma
Non-small cell lung cancer
URLs for this search
API URL:
Copy
Bookmarkable URL:
Copy